Dihexa is a laboratory-made compound with a big reputation and a thin, troubled evidence base — an important combination to understand before anything else. It was built from angiotensin IV, a small fragment of the hormone system that controls blood pressure, which researchers noticed also seemed to sharpen memory in rats. Chemists at Washington State University reshaped it into an orally active, brain-penetrating molecule they called dihexa (its full chemical name is N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide).
In plain terms: an angiotensin-IV-derived nootropic (a "cognitive enhancer") with striking rodent claims, zero human data, and a serious integrity problem in its literature.
What it is
Angiotensin IV is a six-amino-acid piece of the renin–angiotensin system — the hormone network best known for regulating blood pressure. Researchers found that angiotensin IV also had procognitive effects (it improved learning and memory) in rodents, but as a peptide it broke down too fast and could not easily reach the brain.
Dihexa was the engineered answer: a modified, metabolically stabilised version designed to resist breakdown, be taken orally, and cross the blood–brain barrier (the filter that keeps most molecules out of the brain)2. The program was led by John Wright and Joseph Harding.
How it is thought to work
The headline claim is synaptogenesis — the formation of new synapses, the connections through which brain cells communicate. In rodent and cell studies, dihexa was reported to trigger the growth of new dendritic spines (the tiny contact points where synapses form) and to restore memory in impaired animals1.
The proposed mechanism is the HGF/c-Met system — hepatocyte growth factor and its receptor, a signalling pathway that drives cell growth and synapse formation. The idea was that dihexa amplifies this pathway.
Here is the essential caveat, stated plainly: the 2014 paper that provided the central evidence for the HGF/c-Met mechanism was retracted in 2025 after an institutional investigation found the figures contained fabricated and/or falsified data3. So the main mechanistic plank under dihexa is not just unproven — a key piece of it was formally withdrawn from the scientific record.
In plain terms: the "how it works" story rested heavily on a paper that turned out to be untrustworthy. That does not erase every dihexa finding, but it should reset how confidently anyone talks about the mechanism.
Pharmacokinetics and half-life
Dihexa was specifically engineered for stability and oral activity — that was the whole point of modifying angiotensin IV, which is otherwise degraded within minutes. In practice, though, there are no published human pharmacokinetic data at all: no measured human half-life, no human absorption data. Everything known about how it behaves comes from animal work. The absence of human PK data is itself a signal of how early-stage this compound is.
What the studies actually found
The dihexa evidence is entirely preclinical, and part of it is now retracted. Note the level — and the status — in every row.
| Study (cited) | Model / level | Key result | Year |
|---|---|---|---|
| McCoy et al.1 | Rat (aged / scopolamine-impaired) | Metabolically stabilised angiotensin IV analogs, including dihexa, restored memory in impaired rats | 2013 |
| Benoist et al. — RETRACTED3 | Cell + rodent (synaptogenesis) | Claimed dihexa’s effects run through HGF/c-Met; retracted in 2025 for fabricated data | 2014 |
| Wright & Harding — review2 | Review (preclinical) | Framed dihexa as the lead angiotensin-IV analog for possible Alzheimer’s therapy | 2015 |
The pattern is stark. Every result is from cells or rodents; none is from humans. And the single most-cited mechanistic paper is retracted. The 2013 behavioural paper reporting memory restoration in rats also carries a later notice of concern from the journal, so even the non-retracted work sits under a cloud.
In plain terms: interesting rodent claims, a review that promoted them, and a retracted mechanism paper underneath — with no human evidence anywhere.
The honest catch
This is the most important part of the dihexa page. Dihexa has no human data — no clinical trials, no human safety record. Its most eye-catching mechanistic claim was retracted for data fabrication3. The "more potent than BDNF" style claims that circulate online trace back to this compromised preclinical literature. None of that makes dihexa fraudulent as a molecule, but it does mean the confident promises made for it are unsupported. This page describes what studies reported and does not tell anyone how to use anything.
Latest research
- Retraction (2025). The 2014 Benoist paper — long treated as the mechanistic foundation for dihexa’s HGF/c-Met story — was retracted after an investigation found fabricated and/or falsified data3. This is the single most important recent development for anyone reading about dihexa.
- Still no human trials. As of 2026 there are no registered clinical trials and no human safety or efficacy data. The compound remains entirely preclinical.
- The wider angiotensin-IV field continues in animal models for cognition, but dihexa specifically now carries a heavy integrity asterisk that any honest summary has to lead with.
The short version
Dihexa is an angiotensin-IV-derived compound engineered to be orally active and brain-penetrating, reported in rodents to restore memory and build new synapses12. But it has never been tested in humans, and the key paper behind its proposed HGF/c-Met mechanism was retracted in 2025 for fabricated data3. It is strictly a preclinical research compound with a serious evidence-integrity problem. Educational overview only, not medical advice. For context, see what are research peptides.